Grifols SA
(Other OTC/NBB : GIKLY)

( )
GIKLY PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
ABBVAbbVie, Inc. 0.32%90.991.9%$1158.66m
BMYBristol-Myers Squibb Co. 0.58%60.641.0%$1023.48m
JNJJohnson & Johnson 0.70%148.220.7%$986.18m
PFEPfizer Inc. 1.97%36.160.9%$920.93m
MRKMerck & Co., Inc. 1.62%80.850.7%$828.03m
LLYEli Lilly & Co. 0.96%153.911.1%$520.04m
AZNAstraZeneca Plc -0.81%54.721.2%$283.11m
NVSNovartis AG -0.25%86.460.2%$149.88m
GSKGlaxoSmithKline Plc 0.43%42.030.2%$134.22m
NVONovo Nordisk A/S -0.82%65.160.1%$89.77m
SNYSanofi 0.81%49.890.2%$79.33m
RGENRepligen Corp. 2.63%133.377.1%$73.18m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 3.79%66.760.0%$52.59m
TPTXTurning Point Therapeutics, Inc. 3.14%70.390.0%$41.58m
RETAReata Pharmaceuticals, Inc. 0.30%140.333.4%$35.23m

Company Profile

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.